Table 3.

INCPAD Post-Startup Projected Incremental Cost Effectiveness Ratios for New Patients Receiving the Intervention^*

Effectiveness Metric†	Δ Cost per patient	Δ Effectiveness	Incremental Cost-Effectiveness Ratio
DFD (complete follow-ups)	812.55 ($)	60.30 (DFD)	13.48 ($/DFD)
DFD (complete and imputed follow-ups)	812.55 ($)	44.12 (DFD)	18.42 ($/DFD)
QALY (derived from DFD complete follow-ups)	812.55 ($)	.066 to .033 (QALY)	12,311.36 ($/QALY) to 24,622.73 ($/QALY)
QALY (derived from DFD complete and imputed follow-ups)	812.55 ($)	.048 to .024 (QALY)	16,622.13 ($/QALY) to 33,856.25 ($/QALY)
QALY from EQ-5D	665.59 ($)	.088 (QALY)	7,563.52 ($/QALY)
QALY from SF-12 (SF-6D)	665.59 ($)	.013 (QALY)	51,199.23 ($/QALY)

^*Post-start-up costs are projected to be $134,450 for 202 new patients receiving the INCPAD intervention, and $125,132 for the subset of 154 new depressed patients receiving the intervention. This is based upon the assumption that physician and nurse care manager times would be the same for treating the same number of new patients for 12 months as in the trial, but that only automated monitoring maintenance (ASM) costs would be needed since the ASM system would already be set up.

^†DFD = depression-free days. QALY = quality-adjusted life years